The Additional Hetero Ring Is A Cyclo In A Polycyclo Ring System (e.g., Benzofuranyl-benzimidazole, Etc.) Patents (Class 548/305.1)
-
Patent number: 11952479Abstract: Fluorescent orange latexes are provided which comprise water and fluorescent agent-incorporated resin particles, the particles comprising a resin, Solvent Red 49 as a red fluorescent agent, and Solvent Yellow 98 as a yellow fluorescent agent, wherein the fluorescent orange latex has a weight ratio of the Solvent Yellow 98 to the Solvent Red 49 in a range of from 20:1 to 0.5:1. Fluorescent orange toners and methods of making and using the fluorescent orange toners are also provided.Type: GrantFiled: August 18, 2022Date of Patent: April 9, 2024Assignee: Xerox CorporationInventors: Chunliang Lu, Peter V Nguyen, Yu Qi
-
Patent number: 11448981Abstract: Fluorescent latexes are provided. In embodiments, a fluorescent latex comprises water and fluorescent agent-incorporated resin particles, the particles comprising a resin and a Förster Resonance Energy Transfer (FRET) pair comprising a fluorescent brightener having a fluorescence emission spectrum and a fluorescent dye having an absorption spectrum that overlaps with the fluorescence emission spectrum of the fluorescent brightener, wherein the fluorescent latex exhibits FRET under illumination with ultraviolet (UV) light. Fluorescent toners made from the fluorescent latexes are provided. Methods of making and using the fluorescent toners are also provided.Type: GrantFiled: March 18, 2020Date of Patent: September 20, 2022Assignee: Xerox CorporationInventor: Chunliang Lu
-
Patent number: 10160771Abstract: A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.Type: GrantFiled: February 6, 2015Date of Patent: December 25, 2018Assignees: CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD., SICHUAN UNIVERSITYInventors: Yang Zhang, Chunli Shen, Jian Li, Shuhui Chen, Guoping Hu, Yuquan Wei, Luoting Yu, Xin Tao
-
Patent number: 9056874Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: March 14, 2013Date of Patent: June 16, 2015Assignee: NOVARTIS AGInventors: Christopher Michael Adams, Charles Babu, Michael Paul Capparelli, Jian Ding, Takeru Ehara, Keith Jendza, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Liang Xue, Nello Mainolfi, James J. Powers, Michael H. Serrano-Wu, Chun Zhang
-
Publication number: 20150111890Abstract: The present invention provides for compounds of formula (I) wherein A, Y, J, R1, R2, and R3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof,that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).Type: ApplicationFiled: April 19, 2013Publication date: April 23, 2015Inventors: Lisa A. Hasvold, Dachun Liu, Chang Hoon Park, John K. Pratt, George S. Sheppard, Le Wang
-
Publication number: 20150111868Abstract: The present invention is concerned with novel 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, wherein R4, R5, Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.Type: ApplicationFiled: June 14, 2013Publication date: April 23, 2015Applicant: Jansen R&D IrelandInventors: Abdellah Tahri, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Sandrine Marie Helene Vendeville, Lili Hu, Samuel Dominique Demin, Ludwig Paul Cooymans
-
Patent number: 9012039Abstract: A compound for an organic photoelectric device and an organic photoelectric device including the same, the compound being represented by the following Chemical Formula 1:Type: GrantFiled: December 28, 2010Date of Patent: April 21, 2015Assignee: Cheil Industries, Inc.Inventors: Nam-Soo Kim, Myeong-Soon Kang, Sung-Hyun Jung, Ho-Kuk Jung, Kyu-Yeol In, Dong-Min Kang, Eui-Su Kang, Nam-Heon Lee, Seung-Gyoung Lee, Young-Sung Park, Hyon-Gyu Lee, Eun-Sun Yu, Mi-Young Chae
-
Publication number: 20150094304Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.Type: ApplicationFiled: December 11, 2014Publication date: April 2, 2015Inventors: SARA SABINA HADIDA RUAH, PETER DIEDERIK JAN GROOTENHUIS, FREDRICK F. VAN GOOR, JINGLAN ZHOU, BRIAN RICHARD BEAR, MARK THOMAS MILLER, JASON MC CARTNEY, MEHDI MICHEL DJAMEL NUMA
-
Publication number: 20150090963Abstract: An organic compound represented by Formula 1 is disclosed. An organic light-emitting device including the organic compound is also disclosed.Type: ApplicationFiled: February 25, 2014Publication date: April 2, 2015Applicant: SAMSUNG DISPLAY CO., LTD.Inventors: Young-Kook Kim, Kwang-Hyun Kim, Eun-Young Lee
-
Publication number: 20150087685Abstract: Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring System 1, Ring System 2, Ring System 3, Ring System 4 or Ring System 5. Methods of treating disease with phototherapy are also described.Type: ApplicationFiled: April 12, 2013Publication date: March 26, 2015Inventors: Sazzadur Rahman Khan, Shijun Zheng, Sheng Li, Amane Mochizuki, Keisaku Okada
-
Patent number: 8969345Abstract: A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, RA is a hydrogen atom and the like, X is the formula (b3) wherein RB is a hydrogen atom and the like, and the like, A is the formula (a18) wherein R1 is a hydrogen atom and the like, and RC and RD are the same or different and each is a hydrogen atom and the like, and the like, which has a PPAR? agonist activity and the like, and useful as a therapeutic agent and/or prophylaxis agent and the like for type 2 diabetes and the like, or a pharmaceutically acceptable salt thereof and the like is provided.Type: GrantFiled: August 3, 2012Date of Patent: March 3, 2015Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Keisuke Yamamoto, Tomohiro Tamura, Rina Nakamura, Kimihisa Ueno, Shintaro Hosoe
-
Patent number: 8969349Abstract: Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is R1 and R2 together with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R11; L is —C(R6)2—C(R6)2—; B is a heteroaromatic group defined herein; and -A1-A2- , A3, R11 and R6 are defined herein. Also disclosed are methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.Type: GrantFiled: May 26, 2011Date of Patent: March 3, 2015Assignee: Sunovion Pharmaceuticals Inc.Inventors: John Emmerson Campbell, Michael Charles Hewitt, Philip Jones, Linghong Xie
-
Patent number: 8968888Abstract: A novel compound having high triplet excitation energy and a bipolar property is provided. Specifically, a phenanthrene compound represented by General Formula (G1) is provided where R11 to R19 and R21 to R27 separately represent any one of hydrogen, an alkyl group having 1 to 4 carbon atoms, and a substituted or unsubstituted aryl group having 6 to 13 carbon atoms, Ar represents a substituted or unsubstituted arylene group having 6 to 13 carbon atoms, and Z represents a sulfur atom or an oxygen atom. The use of the phenanthrene compound as a host material of a light-emitting layer in the presence of a phosphorescent dopant allows the formation of a light-emitting element with high current efficiency.Type: GrantFiled: October 27, 2011Date of Patent: March 3, 2015Assignee: Semiconductor Energy Laboratory Co., Ltd.Inventors: Yuko Kawata, Hiroshi Kadoma, Nobuharu Ohsawa, Satoshi Seo
-
Patent number: 8962835Abstract: Certain imidazopyrazines of Formula (I): or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.Type: GrantFiled: April 12, 2013Date of Patent: February 24, 2015Assignee: Gilead Connecticut, Inc.Inventors: Scott A. Mitchell, Kevin S. Currie, Peter A. Blomgren, Jeffrey E. Kropf, Seung H. Lee, Jianjun Xu, Douglas G. Stafford
-
Publication number: 20150045551Abstract: The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia.Type: ApplicationFiled: March 29, 2013Publication date: February 12, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Mitsukane Yoshinaga, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Shuhei Kashiwa, Takeshi Kuwada, Youichi Shimazaki
-
Publication number: 20150041773Abstract: An anthracene-based compound is represented by Formula 1 as below: wherein Ar, R1 to R3, R11 to R13, L1, L2, a1 to a3, b1, b2, n1, n2, m1, m2, o1 and o2 are as defined in the specification. An organic light-emitting device includes the anthracene-based compound.Type: ApplicationFiled: May 21, 2014Publication date: February 12, 2015Applicant: SAMSUNG DISPLAY CO., LTD.Inventors: Jun-Ha PARK, Seok-Hwan HWANG, Young-Kook KIM, Hye-Jin JUNG, Eun-Young LEE, Jong-Woo KIM, Jin-O LIM, Sang-Hyun HAN, Kwang-Hyun KIM, Eun-Jae JEONG, Soo-Yon KIM
-
Patent number: 8952177Abstract: The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein X1, X1?, X1?, R1, R2 and R3 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: March 13, 2014Date of Patent: February 10, 2015Assignee: Janssen Pharmaceutica NVInventors: Wenying Chai, Curt A. Dvorak, Wendy Eccles, James P. Edwards, Steven D. Goldberg, Paul J. Krawczuk, Alec D. Lebsack, Jing Liu, Daniel J. Pippel, Zachary S. Sales, Virginia M. Tanis, Mark S. Tichenor, John J. M. Wiener
-
Patent number: 8952873Abstract: Provided are a fused polycyclic compound suitable for use mainly as a component for a blue-light-emitting device, and an organic light-emitting device using the compound. The fused polycyclic compound is represented by the general formulae (1), (2), (8) and (9).Type: GrantFiled: May 1, 2012Date of Patent: February 10, 2015Assignee: Canon Kabushiki KaishaInventors: Hiroki Ohrui, Hironobu Iwawaki, Kei Tagami, Masanori Muratsubaki, Ryuji Ishii
-
Publication number: 20150034927Abstract: A compound represented by the following formula (1-1):Type: ApplicationFiled: February 7, 2013Publication date: February 5, 2015Applicant: Idemitsu Kosan Co., Ltd.Inventors: Yuki Nakano, Hiroshi Yamamoto, Ryohei Hashimoto, Hideaki Nagashima
-
Publication number: 20150011512Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.Type: ApplicationFiled: September 12, 2014Publication date: January 8, 2015Inventors: Steven Albert Everett, Saraj Ulhaq
-
Patent number: 8912199Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.Type: GrantFiled: October 21, 2013Date of Patent: December 16, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Jamel Numa, Xiaoqing Yang
-
Patent number: 8912188Abstract: Disclosed herein are substituted quinoxaline carboxylic acids of Formula (I): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.Type: GrantFiled: March 2, 2012Date of Patent: December 16, 2014Assignee: BioEnergenix, LLCInventors: John M. McCall, Donna L. Romero, Robert C. Kelly
-
Publication number: 20140361268Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound are provided:Type: ApplicationFiled: April 22, 2014Publication date: December 11, 2014Applicant: Samsung Display Co., Ltd.Inventors: Seok-Hwan HWANG, Young-Kook KIM, Jun-Ha PARK, Hye-Jin JUNG, Jin-O LIM, Eun-Young LEE, Sang-Hyun HAN, Eun-Jae JEONG, Soo-Yon KIM, Jong-Hyuk LEE
-
Publication number: 20140343065Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Riccardo GIOVANNINI, Yunhai CUI, Henri DOODS, Marco FERRARA, Stefan JUST, Raimund KUELZER, Iain LINGARD, Rocco MAZZAFERRO, Klaus RUDOLF
-
Publication number: 20140326987Abstract: A compound represented by Formula 1. An organic electric element includes a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode. The organic material layer includes the compound represented by Formula 1. When the organic electric element includes the compound in the organic material layer, luminous efficiency, stability, and life span can be improved.Type: ApplicationFiled: November 13, 2012Publication date: November 6, 2014Inventors: Junghwan Park, Sunhee Lee, Soungyun Mun, Daesung Kim, Hwasoon Jung, Wonsam Kim, Jihun Byun, Bumsung Lee
-
Publication number: 20140323458Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.Type: ApplicationFiled: July 10, 2014Publication date: October 30, 2014Inventors: Jason Allan Wiles, Qiuping Wang, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Venkat Gadhachanda, Avinash Phadke, Milind Deshpande, Dawei Chen
-
Patent number: 8853403Abstract: To provide a novel heterocyclic compound having a bipolar property. To improve element characteristics of a light-emitting element by application of the novel heterocyclic compound to the light-emitting element. A heterocyclic compound represented by a general formula (G1) and a light-emitting element formed using the heterocyclic compound represented by the general formula (G1) are provided. When the heterocyclic compound represented by the general formula (G1) is used for the light-emitting element, the characteristics of the light-emitting element can be improved.Type: GrantFiled: December 7, 2012Date of Patent: October 7, 2014Assignee: Semiconductor Energy Laboratory Co., Ltd.Inventors: Hiroko Nomura, Sachiko Kawakami, Nobuharu Ohsawa, Satoshi Seo
-
Patent number: 8853204Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.Type: GrantFiled: March 18, 2005Date of Patent: October 7, 2014Assignee: Arrow Therapeutics LimitedInventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Dagmar Alber, Lara Wilson, Elisa Henderson, Phil Chambers, Debra Taylor, Stan Tyms, Verity Dowdell
-
Publication number: 20140291654Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein R1 to R12 are defined as in the specification.Type: ApplicationFiled: June 12, 2014Publication date: October 2, 2014Inventors: Young-Kook Kim, Seok-Hwan Hwang, Yoon-Hyun Kwak, Sun-Young Lee, Hye-Jin Jung, Jin-O Lim, Jong-Hyuk Lee
-
Publication number: 20140296519Abstract: A 4-aminocarbazole compound represented by formula (1): wherein Ar1-Ar4 represent substituted or unsubstituted aryl, thienyl, pyridyl, benzothienyl, dibenzothienyl, dibenzofuranyl, 4-carbazolyl, dibenzothienylphenyl, dibenzofuranylphenyl or 9-carbazolylphenyl group; R1-R7 represent substituted or unsubstituted aryl, heteroaryl or heteroarylphenyl group, or alkyl, alkoxy, cyano group, or hydrogen or halogen atom; n is integer of 0-2; and X represents substituted or unsubstituted (n+1)-valent aromatic hydrocarbon, heteroaromatic or heteroarylphenyl group. The 4-aminocarbazole compound provides an organic EL device exhibiting enhanced emitting efficiency and durability.Type: ApplicationFiled: October 25, 2012Publication date: October 2, 2014Applicant: TOSOH CORPORATIONInventors: Naoki Matsumoto, Takanori Miyazaki
-
Publication number: 20140284581Abstract: Disclosed herein are compounds represented by formula: where HT, ET, and R1-R6 are described herein. Compositions of said compounds along with organic light-emitting diode (OLED) devices related thereto are also disclosed.Type: ApplicationFiled: March 21, 2014Publication date: September 25, 2014Applicant: NITTO DENKO CORPORATIONInventor: Shijun Zheng
-
Publication number: 20140284584Abstract: Disclosed herein are compounds represented by the formula: where HT and n are defined herein. Compositions of said compounds along with organic light-emitting diode (OLED) devices related thereto are also disclosed.Type: ApplicationFiled: March 25, 2014Publication date: September 25, 2014Applicant: NITTO DENKO CORPORATIONInventor: Shijun Zheng
-
Publication number: 20140288050Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as pain, neurological disorders, psychiatric disorders, and neuromuscular disorders. Compounds provided herein modulate the activity of opioid receptor (e.g., ?-opioid receptor) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.Type: ApplicationFiled: November 7, 2012Publication date: September 25, 2014Inventors: Scott Malcolm, Carrie Bowen, Laurence Melnick, Linghong Xie
-
Patent number: 8841278Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: October 3, 2013Date of Patent: September 23, 2014Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Eda Canales, Aesop Cho, Jeromy J. Cottell, Manoj C. Desai, Michael Graupe, Hongyan Guo, Randall L. Halcomb, Darryl Kato, Choung U. Kim, Thorsten A. Kirschberg, Evan S. Krygowski, Scott E. Lazerwith, John O. Link, Hongtao Liu, Qi Liu, Richard L. Mackman, Michael L. Mitchell, Jay P. Parrish, Hyung-Jung Pyun, Joseph H. Saugier, Scott D. Schroeder, Jianyu Sun, James G. Taylor, James D. Trenkle, Winston C. Tse, Randall W. Vivian, William J. Watkins, Lianhong Xu
-
Publication number: 20140249196Abstract: The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.Type: ApplicationFiled: November 20, 2012Publication date: September 4, 2014Inventors: Theodore Mark Kamenecka, Patrick R. Griffin, Amy S. Ripka, Jeffrey O. Saunders
-
Patent number: 8822430Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 31, 2013Date of Patent: September 2, 2014Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Eda Canales, Aesop Cho, Jeromy J. Cottell, Manoj C. Desai, Michael Graupe, Hongyan Guo, Randall L. Halcomb, Darryl Kato, Choung U. Kim, Thorsten A. Kirschberg, Evan S. Krygowski, Scott E. Lazerwith, John O. Link, Hongtao Liu, Qi Liu, Richard L. Mackman, Michael L. Mitchell, Jay P. Parrish, Hyung-Jung Pyun, Joseph H. Saugier, Scott D. Schroeder, Jianyu Sun, James G. Taylor, James D. Trenkle, Winston C. Tse, Randall W. Vivian, William J. Watkins, Lianhong Xu
-
Publication number: 20140239260Abstract: A heterocyclic compound is represented by Formula 1. The heterocyclic compound may be used in an organic layer of an organic light-emitting diode. An organic light-emitting diode includes a first electrode, a second electrode and an organic layer, and the organic layer includes the heterocyclic compound represented by Formula 1. The organic light-emitting diode may be used in a flat panel display device, in which the first electrode of the organic light-emitting diode may be electrically connected to a source or drain electrode of a thin film transistor.Type: ApplicationFiled: June 18, 2013Publication date: August 28, 2014Applicant: SAMSUNG DISPLAY CO., LTD.Inventors: Eun-Young Lee, Seok-Hwan Hwang, Young-Kook Kim, Jun-Ha Park, Hye-Jin Jung, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
-
Patent number: 8815864Abstract: The present invention relates to compounds of general formula I, wherein the group (Het)Ar is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.Type: GrantFiled: November 25, 2013Date of Patent: August 26, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Matthias Eckhardt, Elke Langkopf, Holger Wagner
-
Patent number: 8809548Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: February 8, 2010Date of Patent: August 19, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Jeffrey Lee Romine, Denis R. St. Laurent, Makonen Belema, Lawrence B. Snyder, Lawrence G. Hamann, John F. Kadow, Jayne Kapur, Andrew C. Good, Omar D. Lopez, Rico Lavoie, John A. Bender
-
Publication number: 20140228360Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.Type: ApplicationFiled: December 20, 2013Publication date: August 14, 2014Applicant: Epizyme, Inc.Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof
-
Publication number: 20140217393Abstract: An organic electroluminescence device including an anode and a cathode being opposed, wherein a first organic thin film layer and a second organic thin film layer are provided between the anode and the cathode sequentially from the anode side; the first organic thin film layer including an aromatic heterocyclic derivative A represented by the following formula (1-1) and a phosphorescent emitting material; and the second organic thin film layer including an aromatic heterocyclic derivative B represented by the following formula (2-1):Type: ApplicationFiled: September 6, 2012Publication date: August 7, 2014Inventors: Tomoki Kato, Nobuhiro Yabunouchi, Takayasu Sado
-
Publication number: 20140209871Abstract: Provided is a heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound of Formula 1: <Formula 1> wherein substituents in Formula 1 above are defined as in the specification.Type: ApplicationFiled: June 26, 2013Publication date: July 31, 2014Inventors: Jun-Ha Park, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
-
Patent number: 8790794Abstract: A substance having a hole-transport, property and a wide band gap is provided. A heterocyclic compound represented by a general formula (G1) is provided. In the formula, ?1 and ?2 separately represent a substituted or unsubstituted arylene group having 6 to 13 carbon atoms; n and k separately represent 0 or 1; Q1 and Q2 separately represent sulfur or oxygen; and R1 to R22 separately represent hydrogen, an alkyl group having 1 to 12 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 14 carbon atoms.Type: GrantFiled: September 8, 2011Date of Patent: July 29, 2014Assignee: Semiconductor Energy Laboratory Co., Ltd.Inventors: Harue Osaka, Takako Takasu, Nobuharu Ohsawa, Hiromi Nowatari, Satoshi Seo
-
Publication number: 20140206887Abstract: An object is to provide a light-emitting element with high emission efficiency which includes a novel carbazole derivative that has a wide energy gap and can be used for a transport layer or a host material in a light-emitting element. A carbazole derivative in which the 4-position of dibenzothiophene or dibenzofuran is bonded to the 2- or 3-position of carbazole has been able to be provided by use of the carbazole derivative. Further, a light-emitting element having high emission efficiency has been able to be provided by use of the carbazole derivative.Type: ApplicationFiled: March 13, 2014Publication date: July 24, 2014Applicant: Semiconductor Energy Laboratory Co., Ltd.Inventors: Satoshi Seo, Harue Osaka, Sachiko Kawakami, Nobuharu Ohsawa, Tsunenori Suzuki, Hiromi Nowatari, Hiroki Suzuki, Kyoko Takeda
-
Publication number: 20140186878Abstract: Compounds are provided that are either fluorogenic or fluorophoric. Compositions and articles that include the compounds are also provided. Additionally, methods of detecting a microorganism using the compounds are provided. The compounds are fluorinated and can be used advantageously under acidic conditions.Type: ApplicationFiled: March 5, 2012Publication date: July 3, 2014Applicant: 3M INNOVATIVE PROPERTIES COMPANYInventors: Stephen B. Roscoe, Shih-Hung Chou, Stephanie J. Moeller, Jesse D. Miller, Kurt J. Halverson, Jason W. Bjork
-
Patent number: 8765748Abstract: The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 19, 2008Date of Patent: July 1, 2014Assignee: University Health NetworkInventors: Heinz W. Pauls, Bryan T. Forrest, Radoslaw Laufer, Miklos Feher, Peter Brent Sampson, Guohua Pan, Sze-Wan Li, Yong Liu
-
Publication number: 20140179750Abstract: The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.Type: ApplicationFiled: June 19, 2012Publication date: June 26, 2014Applicant: EMORY UNIVERSITYInventors: Jianxiong Jiang, Thota Ganesh, Yuhong Du, Pahk Thepchatri, Yi Quan, Ray J. Dingledine
-
Patent number: 8759535Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.Type: GrantFiled: February 16, 2011Date of Patent: June 24, 2014Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
-
Publication number: 20140163237Abstract: Some embodiments provide a compound represented by Formula 1: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are independently H, C1-C3 alkyl, or C1-3 perfluoroalkyl; HT is optionally substituted carbazoyl, optionally substituted phenylcarbazolyl, optionally substituted (phenylcarbazolyl)phenyl, optionally substituted phenylnaphthylamine, or optionally substituted diphenylamine; and ET optionally substituted benzimidazol-2-yl, optionally substituted benzothiazol-2-yl, optionally substituted benzoxazol-2-yl, optionally substituted 3,3?-bipyridin-5-yl, optionally substituted quinolin-8-yl, optionally substituted quinolin-5-yl, or optionally substituted quinoxalin-5-yl. Other embodiments provide an organic light-emitting diode device comprising a compound of Formula 1.Type: ApplicationFiled: December 10, 2013Publication date: June 12, 2014Applicant: NITTO DENKO CORPORTIONInventors: David T. Sisk, Shijun Zheng
-
Patent number: 8748433Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of b3-adrenoceptor.Type: GrantFiled: April 25, 2011Date of Patent: June 10, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Richard Berger, Scott D. Edmondson, Bart H. Harper